Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
Additional cardiac biomarker analyses further demonstrate ifetroban's cardioprotective effect in DMD patients NASHVILLE, Tenn., June 26, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-focused biopharmaceutical company committed to developing new...
Additional cardiac biomarker analyses further demonstrate ifetroban's cardioprotective effect in DMD patients NASHVILLE, Tenn., June 26, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-focused biopharmaceutical company committed to developing new...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.